Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

NCT01818011
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 2 Interventional

A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

NCT00033111
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Torrance, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Not applicable Interventional Results available

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

NCT01065571
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
carrageenan, dietary intervention with no-carrageenan diet
Dietary Supplement · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

NCT01197534
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo, fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Not applicable Interventional

Speed of Processing Training to Improve Cognition in Traumatic Brain Injury and Mild Cognitive Impairment

NCT02020564
View directory record Official record
Conditions
Traumatic Brain Injury, Mild Cognitive Impairment
Interventions
Speed of Processing Training, Placebo Control
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 59 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 30, 2026, 10:23 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™

NCT02221232
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chloraprep, ZuraPrep, ZuraPrep Vehicle
Drug
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer

NCT02556632
View directory record Official record
Conditions
Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
Interventions
Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Newark, Delaware • Decatur, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

Steroids In Eosinophil Negative Asthma

NCT02066298
View directory record Official record
Conditions
Asthma
Interventions
Mometasone 220mcg BID, Tiotropium Respimat 5mcg QD, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

NCT05665387
View directory record Official record
Conditions
Presbyopia
Interventions
0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
47 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Glendale, California • Newport Beach, California • Morrow, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT05096221
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, placebo
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.

NCT05026216
View directory record Official record
Conditions
Cellulite
Interventions
Qwo
Drug
Lead sponsor
DMR Research, PLLC
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

NCT02289716
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
El Cajon, California • Sherman Oaks, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 30, 2026, 10:23 AM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321
View directory record Official record
Conditions
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions
TTHX1114(NM141), Vehicle (placebo)
Drug · Other
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 30, 2026, 10:23 AM EDT
Suspended Phase 2 Interventional

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

NCT04482621
View directory record Official record
Conditions
COVID-19
Interventions
Decitabine, Placebo Saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries

NCT02290821
View directory record Official record
Conditions
Acute Blunt Soft Tissue Injuries/Contusions
Interventions
placebo, Placebos
Drug
Lead sponsor
Novartis
Industry
Eligibility
16 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Bradenton, Florida • Port Orange, Florida • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

NCT02229214
View directory record Official record
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Turmeric and Turmeric-containing Tablets and Sebum Production

NCT03065504
View directory record Official record
Conditions
Skin Inflammation
Interventions
Turmeric, Turmeric-containing combination tablet, Placebo tablets
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

NCT02227147
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
rhNGF 20µg/ml, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 4 Interventional Results available

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

NCT03247738
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Cangrelor, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Fentanyl

NCT04136548
View directory record Official record
Conditions
Healthy
Interventions
Fentanyl, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

NCT03259555
View directory record Official record
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 30, 2026, 10:23 AM EDT
Completed Phase 1 Interventional

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

NCT01493726
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Hoffman Estates, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 30, 2026, 10:23 AM EDT